Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Expanded CD34+ Haemopoietic cells
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Portal Vein Infusion
01
Overview
This is an experimental autologous cell therapy developed by Imperial College London for the treatment of chronic liver insufficiency and end-stage liver failure. The therapeutic process involves the mobilization of a patient's own CD34+ hematopoietic stem and progenitor cells using granulocyte colony-stimulating factor (G-CSF), followed by collection via leukapheresis. These cells are then expanded ex vivo in a Good Manufacturing Practice (GMP) facility before being infused back into the patient through either the hepatic artery or the portal vein. The treatment is designed to stimulate liver regeneration and repair damaged hepatic tissue. Clinical results from Phase I/II trials have indicated that the procedure is safe and may lead to improvements in liver function markers such as serum albumin and bilirubin levels.
- Other names
- Autologous CD34+ Stem CellsExpanded Adult Haematopoietic Stem Cells
Beyond the preview
Go deeper on Autologous Expanded CD34+ Haemopoietic cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Expanded CD34+ Haemopoietic cells.